Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer (Q24245085)

2

0 references

Andrew Strickland

3

0 references

Christopher B Steer

4

0 references

David Goldstein

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Objective response to treatment as a potential surrogate marker of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Treatment of Unresectable Pancreatic Carcinoma with 5-Fluorouracil, Vincristine, and CCNU

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002093.PUB2

7 January 2021

Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002093.PUB2

Identifiers

DOI

10.1002/14651858.CD002093.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

4343933

4343933

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference